Intratio
Quantitative Research
Skip to main content
AI Market Summary
Loading market intelligence...
AI 90-DAY FORECAST
NEUTRAL SIGNAL
██.█% Sign up free to reveal

Merus N.V. (MRUS) AI Forecast

Our AI analyzed Merus N.V.. Create a free account to see the 90-day price prediction.

Free account • 30-day free trial

$MRUS Neutral Signal Full forecast available

Merus N.V. (MRUS) Stock Forecast 2025


Merus N.V. (MRUS) AI Stock Price Forecast & Investment Analysis

Merus N.V. Stock Price Chart and Technical Analysis

Loading chart...

Merus N.V. (MRUS) - Comprehensive Stock Analysis & Investment Research

Deep dive into Merus N.V.'s business profile, financial performance, AI predictions, and competitive positioning to make informed investment decisions.

Analysis updated on May 1, 2026, 10:58 p.m. (UTC)

Merus N.V. Investment Summary

When evaluating whether Merus N.V. (MRUS) represents a compelling investment opportunity, investors must consider multiple factors including the company's financial health, market position, growth prospects, and what our AI-powered predictive models suggest about its near-term price trajectory.

Company Profile

Merus N.V. (MRUS) operates within the Life Sciences sector, specifically in the Pharmaceutical Preparations industry. The company employs approximately 202 people. With a market capitalization of $7 billion, the company is a mid-cap stock that typically offers a balance between growth potential and established business operations.

Financial Performance Analysis

Our comprehensive financial analysis covers Merus N.V.'s revenue, profitability metrics, balance sheet strength, and cash flow generation...

AI Price Predictions

Get AI-powered 7-day, 30-day and 90-day price forecasts for Merus N.V. along with confidence scores and detailed analysis...

Investment Considerations

Expert analysis of whether Merus N.V. is suitable for your investment objectives, risk tolerance, and time horizon...

Continue Reading Full Analysis

Get the complete investment breakdown for Merus N.V.

Sign Up Free
Corporate Identity

Merus N.V. (Stock Symbol: MRUS) is a prominent company operating within the Life Sciences sector, with a specific focus on the Pharmaceutical Preparations industry. The company's shares are publicly traded on the Nasdaq exchange.

Leadership & Workforce

Detailed information about Merus N.V.'s leadership team, workforce size, and organizational structure...

Market Classification

Market capitalization analysis and stock classification (mega-cap, large-cap, mid-cap, small-cap) for Merus N.V....

Sector & Industry Analysis

In-depth sector dynamics and industry context for Merus N.V....

Unlock Full Company Profile

Get complete details about Merus N.V.

Sign Up Free
Revenue & Growth Analysis

Merus N.V. generates annual revenues of $56 million , representing an emerging company in its growth phase.

Profitability Metrics

Net profit margin, gross margin, and operating margin analysis for Merus N.V....

Market Valuation

P/E ratio, price-to-book, and valuation multiples for Merus N.V....

Return Metrics

Return on equity (ROE), return on assets (ROA), and capital efficiency for Merus N.V....

Unlock Financial Analysis

Get complete financial metrics for Merus N.V.

Sign Up Free
AI ANALYSIS AVAILABLE

Unlock Merus N.V.'s AI Price Forecast

Join 10,000+ investors using our 67%+ accurate AI predictions

4,000+ Stocks Analyzed
67%+ Accuracy Rate
Daily Updates
Start 30-Day Free Trial

30-day free trial • Cancel anytime

Strategic Market Position

Merus N.V. strategically competes in the highly dynamic Pharmaceutical Preparations marketplace. As a mid-cap company, it occupies an attractive position balancing growth potential with established operations. Mid-caps often represent the 'sweet spot' for investors seeking companies that have proven their business models but still have meaningful runway for expansion. These companies are large enough to have competitive advantages but nimble enough to adapt quickly to market changes.

Industry Competitive Landscape

Merus N.V. competes within the Life Sciences sector, navigating the competitive dynamics and market forces specific to this industry. The company's competitive position depends on its ability to differentiate through product quality, cost efficiency, customer relationships, or other strategic advantages relevant to its specific market segment.

Operational Efficiency

The company currently shows negative free cash flow of $-126 million . Negative free cash flow may reflect heavy investment in growth, working capital needs, or operational challenges. This is common for high-growth companies investing aggressively but warrants attention for mature businesses.

Margin & Pricing Power Analysis

The company maintains a 100.0% gross margin which reflects exceptional pricing power and/or an asset-light business model. Gross margins at this level are typically seen in software, pharmaceuticals, or luxury goods companies where the cost of incremental production is minimal relative to selling prices. Such margins indicate significant competitive advantages protecting the company from price-based competition.

Operating margin of -642.8% demonstrates how efficiently the company converts revenues into operating profits after accounting for all operating expenses including research and development, sales and marketing, and general administrative costs. Operating margin compression relative to gross margin suggests high operating expenses that may warrant efficiency improvements or reflect necessary growth investments.

Asset Utilization Efficiency

Asset turnover ratio of 0.13x indicates lower asset turnover that may reflect the industry's capital-intensive nature or potentially underutilized assets. Companies with low turnover typically depend on strong margins to generate adequate returns on capital.

Financial Strength & Leverage

Current ratio of 6.17 demonstrates strong short-term liquidity with current assets significantly exceeding current liabilities. This provides a substantial buffer for meeting near-term obligations and handling unexpected financial needs.

Merus N.V. (MRUS) Fundamental Analysis & Insider Trading Data (Quarterly Financial Reports)

Comprehensive quarterly financial data, earnings trends, insider transactions, and institutional holdings for Merus N.V. stock analysis.

Deep dive into Merus N.V.'s financial health, valuation metrics, and operational efficiency to make informed investment decisions.

Understanding Valuation Metrics

What these metrics mean: Valuation metrics help determine if Merus N.V. stock is fairly priced compared to its earnings, assets, and market position.

How to read them: Lower P/E ratios may indicate undervalued stocks, while higher ratios suggest growth expectations. P/B ratio compares market value to book value.

For Merus N.V.: With a P/E ratio of -13.46, the market sees the stock as potentially undervalued.

P/E Ratio -13.46x
P/B Ratio 8.81x
Market Cap $6.83B
EPS $-5.58
Book Value/Share $10.22
Revenue/Share $0.75
FCF/Share $-2.69
Understanding Profitability Metrics

What these metrics mean: These ratios measure how efficiently Merus N.V. converts revenue into profit and generates returns for shareholders.

How to read them: Higher ROE/ROA indicate better management efficiency. Margin percentages show profit at different operational levels.

For Merus N.V.: An ROE of -28.3% indicates room for improvement in shareholder value creation.

ROE -28.3%
ROA -18.5%
ROIC -27.9%
Gross Margin 100.0%
Operating Margin -642.8%
Net Margin -680.6%
EBT Margin -143.6%
Understanding Financial Health Metrics

What these metrics mean: These ratios assess Merus N.V.'s ability to meet short-term obligations and manage debt levels effectively.

How to read them: Current ratio >2 is generally good, Quick ratio >1 shows strong liquidity. Lower D/E ratios indicate conservative debt management.

For Merus N.V.: A current ratio of 6.17 indicates strong liquidity.

Current Ratio 6.17x
Quick Ratio 5.88x
D/E Ratio 0.01x
Financial Leverage 1.40x
Interest Coverage -5.7x
Working Capital $171M
Understanding Cash Flow Metrics

What these metrics mean: Cash flow metrics reveal Merus N.V.'s ability to generate cash from operations and fund growth initiatives.

How to read them: Positive operating cash flow is crucial. Free cash flow shows money available for dividends, buybacks, or investments.

For Merus N.V.: Free cash flow of $-126M indicates cash challenges that need attention.

Operating Cash Flow -$125M
Free Cash Flow -$126M
Capital Spending -$1M
FCF/Sales -241.2%
CapEx/Sales 2.0%
Understanding Operational Efficiency Metrics

What these metrics mean: These ratios measure how effectively Merus N.V. uses its assets and manages working capital.

How to read them: Higher turnover ratios indicate efficient asset utilization. Shorter collection periods show effective credit management.

For Merus N.V.: An asset turnover of 0.13x suggests room for improvement in asset utilization.

Asset Turnover 0.13x
Receivables Turnover 22.8x
Fixed Assets Turnover 7.4x
Days Sales Outstanding 16 days
Payables Period 42 days
Understanding Financial Statement Data

What these metrics mean: Key figures from Merus N.V.'s income statement and balance sheet showing absolute financial performance.

How to read them: Revenue shows business scale, while margins indicate profitability. Balance sheet items reveal financial structure.

For Merus N.V.: With annual revenue of $56M, Merus N.V. represents a smaller but potentially high-growth operation.

Income Statement
Total Revenue $56M
R&D Expense $192M
SG&A Expense $83M
Cost of Goods Sold -$165M
Balance Sheet Highlights (% Of Assets)
Total Current Assets 91%
Cash & Short-term Investments 86%
Total Liabilities 29%
Short-term Debt 0%
Accounts Receivable 1%
Dividend & Shareholder Information
Shares Outstanding 76M
Growth Metrics (YoY)
EPS Growth -9.5%

Latest Merus N.V. Stock News & Market Analysis

Breaking news, analyst reports, and market updates affecting Merus N.V. (MRUS) stock price and investment outlook.

📰 We are currently updating our news feed for Merus N.V.. Check back soon for the latest market analysis and company updates.

Merus N.V. Competitors & Peer Analysis - Life Sciences Sector

Comparative analysis of Merus N.V. against industry peers and competitors in the Life Sciences sector, featuring AI-powered forecasts and key financial metrics.

Company Ticker Symbol 90-Day AI Forecast Market Cap (USD M) P/E Ratio P/B Ratio
Aardvark Therapeutics, Inc. AARD ██% $119M x 1.1x
Abbvie Inc. ABBV ██% $365.42B 86.5x x
Abcellera Biologics Inc. ABCL ██% $1.33B x 1.4x
Abeona Therapeutics Inc. ABEO ██% $299M 4.2x 1.9x
Abbott Laboratories ABT ██% $155.82B 24.8x 3.0x
Arbutus Biopharma Corp ABUS ██% $832M x 10.9x
Abvc Biopharma, Inc. ABVC ██% $26M x 2.3x
Abivax S.A. ABVX ██% $9.24B x x
Acadia Pharmaceuticals Inc ACAD ██% $3.74B 9.6x 3.1x
Adicet Bio, Inc. ACET ██% $77M x 0.5x
Aclaris Therapeutics, Inc. ACRS ██% $616M x 6.0x
Acrivon Therapeutics, Inc. ACRV ██% $81M x 0.7x
Actuate Therapeutics, Inc. ACTU ██% $120M x 11.0x
Accustem Sciences Inc. ACUT ██% $4M x x
Acurx Pharmaceuticals, Inc. ACXP ██% $6M x 1.2x
Adagene Inc. ADAG ██% $252M x 6.7x
Adc Therapeutics Sa ADCT ██% $482M x x
Adial Pharmaceuticals, Inc. ADIL ██% $2M x 0.4x
Aditxt, Inc. ADTX ██% $180K x 0.0x
Addex Therapeutics Ltd. ADXN ██% $9M x x
Aeon Biopharma, Inc. AEON ██% $23M x x
Agios Pharmaceuticals, Inc. AGIO ██% $1.67B x 1.5x
Ainos, Inc. AIMD ██% $12M x 1.7x
Akebia Therapeutics, Inc. AKBA ██% $372M x 11.4x
Akero Therapeutics, Inc. AKRO ██% $4.38B -8.7x 4.6x
Akari Therapeutics Plc AKTX ██% $6M x 0.2x
Aldeyra Therapeutics, Inc. ALDX ██% $96M x 2.2x
Alkermes Plc. ALKS ██% $5.53B 22.9x 3.0x
Allarity Therapeutics, Inc. ALLR ██% $21M x 2.1x
Alumis Inc. ALMS ██% $3.20B x 10.6x
Alnylam Pharmaceuticals, Inc. ALNY ██% $39.20B 124.9x 49.7x
Altimmune, Inc. ALT ██% $548M x 2.4x
Alx Oncology Holdings Inc ALXO ██% $227M x 8.8x
Alzamend Neuro, Inc. ALZN ██% $4M x 2.0x
Amylyx Pharmaceuticals, Inc. AMLX ██% $1.76B x 5.8x
Amphastar Pharmaceuticals, Inc. AMPH ██% $999M 10.2x 1.3x
Amarin Corp Plc\Uk AMRN ██% $295M x 0.7x
Amneal Pharmaceuticals, Inc. AMRX ██% $4.02B 55.8x x
Anaptysbio, Inc ANAB ██% $1.94B x 52.2x
Anebulo Pharmaceuticals, Inc. ANEB ██% $19M x 2.4x
Ani Pharmaceuticals Inc ANIP ██% $1.81B 23.1x 3.3x
Anixa Biosciences Inc ANIX ██% $105M x 7.0x
Annexon, Inc. ANNX ██% $859M x 4.1x
Alto Neuroscience, Inc. ANRO ██% $796M x 5.3x
An2 Therapeutics, Inc. ANTX ██% $168M x 3.2x
Annovis Bio, Inc. ANVS ██% $69M x 4.1x
Apollomics Inc. APLM ██% $36M x x
Apellis Pharmaceuticals, Inc. APLS ██% $5.24B 234.2x 14.2x
Applied Therapeutics, Inc. APLT ██% $15M -0.7x 0.9x
Aprea Therapeutics, Inc. APRE ██% $10M x 0.8x
Apimeds Pharmaceuticals Us, Inc. APUS ██% $2M x 0.3x
Aptevo Therapeutics Inc. APVO ██% $6M x 0.3x
Aquestive Therapeutics, Inc. AQST ██% $513M x x
Arcturus Therapeutics Holdings Inc. ARCT ██% $245M x 1.2x
Ardelyx, Inc. ARDX ██% $1.70B x 11.4x
Arcutis Biotherapeutics, Inc. ARQT ██% $2.88B x 15.2x
Artelo Biosciences, Inc. ARTL ██% $3M x x
Arvinas, Inc. ARVN ██% $667M x 1.5x
Arrowhead Pharmaceuticals, Inc. ARWR ██% $10.28B 50.8x 18.1x
Aspire Biopharma Holdings, Inc. ASBP ██% $1M x x
Assembly Biosciences, Inc. ASMB ██% $434M x 2.1x
Ascendis Pharma A/S ASND ██% $13.69B x x
Assertio Holdings, Inc. ASRT ██% $119M x 1.3x
Atai Beckley N.V. ATAI ██% $1.52B x 9.5x
Alterity Therapeutics Ltd ATHE ██% $89M x x
Actinium Pharmaceuticals, Inc. ATNM ██% $35M x 4.5x
Atossa Therapeutics, Inc. ATOS ██% $46M x 1.2x
Avenue Therapeutics, Inc. ATXI ██% $2M x 0.9x
Astria Therapeutics, Inc. ATXS ██% $710M -4.7x 3.0x
Aurinia Pharmaceuticals Inc. AUPH ██% $2.03B 7.1x 3.5x
Arrivent Biopharma, Inc. AVBP ██% $1.27B x 4.1x
Avadel Pharmaceuticals Plc AVDL ██% $2.10B -10.2x 21.4x
Atea Pharmaceuticals, Inc. AVIR ██% $436M x 1.6x
Avalo Therapeutics, Inc. AVTX ██% $312M x 3.8x
Axim Biotechnologies, Inc. AXIM ██% $2M x x
Axsome Therapeutics, Inc. AXSM ██% $10.51B x 119.0x
Aytu Biopharma, Inc AYTU ██% $27M -0.3x 1.2x
Azitra, Inc. AZTR ██% $4M x 1.1x
Bridgebio Pharma, Inc. BBIO ██% $13.35B x x
Bridgebio Oncology Therapeutics, Inc. BBOT ██% $671M x 1.6x
Bicara Therapeutics Inc. BCAX ██% $1.42B x 3.5x
Briacell Therapeutics Corp. BCTX ██% $30M x 1.0x
Bicycle Therapeutics Plc BCYC ██% $335M x 0.6x
Bioadaptives, Inc. BDPT ██% $150K x x
Biodexa Pharmaceuticals Plc BDRX ██% $510K x x
Beone Medicines Ltd. BEIGF ██% $36.38B 530.6x 8.8x
Bullfrog Ai Holdings, Inc. BFRG ██% $13M x 6.0x
Biofrontera Inc. BFRI ██% $13M x 1.2x
Bio Green Med Solution, Inc. BGMS ██% $5M x 0.8x
Bausch Health Companies Inc. BHC ██% $2.11B x x
Bioharvest Sciences Inc. BHST ██% $95M x 3.7x
Biohaven Ltd. BHVN ██% $1.22B -4.6x 23.4x
Bioage Labs, Inc. BIOA ██% $745M x 2.7x
Bio Essence Corp BIOE ██% $19M 21.2x x
Biovie Inc. BIVI ██% $13M x 0.7x
Bioxytran, Inc BIXT ██% $3M x x
Biolinerx Ltd. BLRX ██% $13M x x
Belite Bio, Inc BLTE ██% $6.09B x 7.9x
Biomea Fusion, Inc. BMEA ██% $99M x 3.4x
Biomarin Pharmaceutical Inc BMRN ██% $10.40B 29.8x 1.7x
Bristol Myers Squibb Co BMY ██% $118.65B 16.3x 5.9x
Bristol Myers Squibb Co BMYMP ██% $1.73T 287.0x 93.4x
Benitec Biopharma Inc. BNTC ██% $409M x 2.2x
Boundless Bio, Inc. BOLD ██% $35M x 0.4x
Bolt Biotherapeutics, Inc. BOLT ██% $10M x 0.4x
Bio-Path Holdings, Inc. BPTH ██% $510K x x
Bioquest Corp BQST ██% $2M x x
Barinthus Biotherapeutics Plc. BRNS ██% $27M x 0.4x
Bespoke Extracts, Inc. BSPK ██% $3M x x
Bioxcel Therapeutics, Inc. BTAI ██% $32M x x
Beyondspring Inc. BYSI ██% $61M x x
Calcimedica, Inc. CALC ██% $9M x x
Camp4 Therapeutics Corp CAMP ██% $208M -0.1x 4.4x
Can-Fite Biopharma Ltd. CANF ██% $6M x 1.1x
Capricor Therapeutics, Inc. CAPR ██% $1.93B x 6.3x
Carisma Therapeutics Inc. CARM ██% $30K 0.0x x
Casi Pharmaceuticals, Inc. CASI ██% $5M -1.4x 2.5x
Perspective Therapeutics, Inc. CATX ██% $445M x 2.2x
Gyre Therapeutics, Inc. CBIO ██% $681M 69.0x 6.4x
Cdt Equity Inc. CDT ██% $11M x 2.6x
Cingulate Inc. CING ██% $65M x 25.8x
Cell Source, Inc. CLCS ██% $56M x x
Clene Inc. CLNN ██% $67M x x
Cellectar Biosciences, Inc. CLRB ██% $11M x 1.3x
Clearside Biomedical, Inc. CLSD ██% $4M -2.0x -0.7x
Clearside Biomedical, Inc. CLSDQ ██% $2M x x
Climb Bio, Inc. CLYM ██% $424M x 2.6x
Chemomab Therapeutics Ltd. CMMB ██% $11M x 0.9x
Clearmind Medicine Inc. CMND ██% $2M x x
Compass Pathways Plc CMPS ██% $1.22B x x
Cnbx Pharmaceuticals Inc. CNBX ██% $340K x x
Cns Pharmaceuticals, Inc. CNSP ██% $2M x 0.4x
Centessa Pharmaceuticals Plc CNTA ██% $5.88B x 11.2x
Connect Biopharma Holdings Ltd CNTB ██% $139M x 3.3x
Canton Strategic Holdings, Inc. CNTN ██% $179M x 0.5x
Context Therapeutics Inc. CNTX ██% $207M x 3.4x
Cocrystal Pharma, Inc. COCP ██% $19M x 3.0x
Cogent Biosciences, Inc. COGT ██% $5.76B x 9.1x
Collegium Pharmaceutical, Inc COLL ██% $1.08B 17.2x 3.6x
Corcept Therapeutics Inc CORT ██% $4.86B 102.6x 7.6x
Coya Therapeutics, Inc. COYA ██% $99M x 2.3x
China Pharma Holdings, Inc. CPHI ██% $22M x 2.6x
Cumberland Pharmaceuticals Inc CPIX ██% $63M x 2.5x
Cannapharmarx, Inc. CPMD ██% $2M x x
Catalyst Pharmaceuticals, Inc. CPRX ██% $3.44B 16.1x 3.6x
Corbus Pharmaceuticals Holdings, Inc. CRBP ██% $174M x 1.2x
Cormedix Inc. CRMD ██% $602M 3.7x 1.5x
Crinetics Pharmaceuticals, Inc. CRNX ██% $3.71B x 3.7x
Cervomed Inc. CRVO ██% $34M x 1.9x
Corvus Pharmaceuticals, Inc. CRVS ██% $1.28B x 20.9x
Cytomx Therapeutics, Inc. CTMX ██% $912M x 9.2x
Contineum Therapeutics, Inc. CTNM ██% $479M x 1.8x
Citius Oncology, Inc. CTOR ██% $75M x 1.3x
Hepion Pharmaceuticals, Inc. CTRVP ██% $20K x 0.0x
Ctt Pharmaceutical Holdings, Inc. CTTH ██% $4M x 5.9x
Citius Pharmaceuticals, Inc. CTXR ██% $19M x 0.2x
Cue Biopharma, Inc. CUE ██% $48M x 1.8x
Curanex Pharmaceuticals Inc CURX ██% $12M x 1.1x
Cadrenal Therapeutics, Inc. CVKD ██% $16M x 5.7x
Cv Sciences, Inc. CVSI ██% $5M x 3.7x
Cyclerion Therapeutics, Inc. CYCN ██% $14M x 1.6x
Cytodyn Inc. CYDY ██% $420M x x
Cypherpunk Technologies Inc. CYPH ██% $75M 15.5x 0.5x
Cryoport, Inc. CYRX ██% $511M 6.5x 1.0x
Cytokinetics Inc CYTK ██% $7.95B x x
Dare Bioscience, Inc. DARE ██% $33M x 11.6x
Day One Biopharmaceuticals, Inc. DAWN ██% $2.22B x 5.0x
Decoy Therapeutics Inc. DCOY ██% $3M x 0.5x
Journey Medical Corp DERM ██% $171M x 5.4x
Diamedica Therapeutics Inc. DMAC ██% $325M x 5.8x
Damora Therapeutics, Inc. DMRA ██% $1.55B x 6.4x
Dianthus Therapeutics, Inc. /De/ DNTH ██% $4.75B x 9.6x
Dermata Therapeutics, Inc. DRMA ██% $6M x 0.9x
Bright Minds Biosciences Inc. DRUG ██% $861M x x
Design Therapeutics, Inc. DSGN ██% $849M x 3.9x
Dynavax Technologies Corp DVAX ██% $1.82B 88.2x 3.4x
Dogwood Therapeutics, Inc. DWTX ██% $49M x 0.7x
Dyne Therapeutics, Inc. DYN ██% $2.89B x 3.0x
Emergent Biosolutions Inc. EBS ██% $429M 8.2x 0.8x
Edesa Biotech, Inc. EDSA ██% $152M x 10.9x
Eagle Pharmaceuticals, Inc. EGRX ██% $4M 0.4x 0.0x
Pmgc Holdings Inc. ELAB ██% $11M x 1.4x
Elanco Animal Health Inc ELAN ██% $11.12B x 1.7x
Eledon Pharmaceuticals, Inc. ELDN ██% $276M x 3.4x
Elite Pharmaceuticals Inc /Nv/ ELTP ██% $365M 13.4x 4.6x
Elicio Therapeutics, Inc. ELTX ██% $203M x 123.8x
Enliven Therapeutics, Inc. ELVN ██% $2.51B x 5.5x
Emmaus Life Sciences, Inc. EMMA ██% $640K x x
Enlivex Ltd. ENLV ██% $198M 0.1x 0.1x
Ensysce Biosciences, Inc. ENSC ██% $3M x 1.1x
Enanta Pharmaceuticals Inc ENTA ██% $403M x 3.2x
Gridai Technologies Corp. ENTO ██% $7M 0.0x 0.3x
Enveric Biosciences, Inc. ENVB ██% $8M x 1.9x
Evolus, Inc. EOLS ██% $350M x x
Essa Pharma Inc. EPIX ██% $9M -2.7x 0.1x
Eupraxia Pharmaceuticals Inc. EPRX ██% $480M x 5.9x
Equillium, Inc. EQ ██% $125M x 4.4x
Erasca, Inc. ERAS ██% $2.89B x 8.9x
Ernexa Therapeutics Inc. ERNA ██% $4M x 1.8x
Esperion Therapeutics, Inc. ESPR ██% $515M x x
89bio, Inc. ETNB ██% $2.20B -3.5x 4.2x
Eton Pharmaceuticals, Inc. ETON ██% $652M x 24.9x
Earth Science Tech, Inc. ETST ██% $41M 10.0x 7.1x
Evofem Biosciences, Inc. EVFM ██% $820K 2.1x x
Evommune, Inc. EVMN ██% $857M x 4.2x
Edgewise Therapeutics, Inc. EWTX ██% $3.29B x 6.3x
Fuss Brands Corp. FBDS ██% $2M x 0.0x
Fortress Biotech, Inc. FBIO ██% $73M 10.8x 1.5x
Fortress Biotech, Inc. FBIOP ██% $394M 98.8x 7.1x
Fibrobiologics, Inc. FBLG ██% $6M x 2.3x
Forte Biosciences, Inc. FBRX ██% $546M x 9.0x
Fibrogen Inc FGEN ██% $35M 0.2x -3.6x
Foghorn Therapeutics Inc. FHTX ██% $269M x x
Filana Therapeutics, Inc. FLNA ██% $70M x 0.9x
Amicus Therapeutics, Inc. FOLD ██% $4.50B x 16.4x
Fulcrum Therapeutics, Inc. FULC ██% $475M x 1.4x
Galectin Therapeutics Inc GALT ██% $148M x x
Gain Therapeutics, Inc. GANX ██% $80M x 4.3x
Generation Bio Co. GBIO ██% $36M -0.6x 0.7x
Greater Cannabis Company, Inc. GCAN ██% $190K x x
Cytomed Therapeutics Ltd GDTC ██% $12M x x
Geron Corp GERN ██% $985M x 4.4x
Gh Research Plc GHRS ██% $1.27B x x
Galmed Pharmaceuticals Ltd. GLMD ██% $4M x 0.2x
Galapagos Nv GLPG ██% $1.83B x x
Greenwich Lifesciences, Inc. GLSI ██% $337M x 154.4x
Galecto, Inc. GLTO ██% $1.59B -2.5x 198.2x
Genelux Corp GNLX ██% $121M x 10.5x
Genprex, Inc. GNPX ██% $8M x 1.0x
Gossamer Bio, Inc. GOSS ██% $86M x x
Geovax Labs, Inc. GOVX ██% $3M x 0.7x
Structure Therapeutics Inc. GPCR ██% $3.03B x 2.0x
Grace Therapeutics, Inc. GRCE ██% $37M x 0.6x
Gridai Technologies Corp. GRDX ██% $8M x 0.4x
Gri Bio, Inc. GRI ██% $3M x 0.5x
Galera Therapeutics, Inc. GRTX ██% $16M 0.1x 4.0x
Gsk Plc GSK ██% $104.41B x x
Gt Biopharma, Inc. GTBP ██% $11M x 1.9x
Gyre Therapeutics, Inc. GYRE ██% $701M 71.0x 6.6x
Hutchmed (China) Ltd HCM ██% $2.30B 2.5x 1.9x
Hcw Biologics Inc. HCWB ██% $3M x 1.1x
Cybin Inc. HELP ██% $265M x x
Hepion Pharmaceuticals, Inc. HEPA ██% $2M x 0.6x
Vyome Holdings, Inc HIND ██% $14M x 5.8x
Hutchmed (China) Ltd HMDCF ██% $2.64B x 2.1x
Hookipa Pharma Inc. HOOK ██% $15M x 0.4x
Hoth Therapeutics, Inc. HOTH ██% $14M x 2.3x
Werewolf Therapeutics, Inc. HOWL ██% $35M x 1.4x
Harmony Biosciences Holdings, Inc. HRMY ██% $1.82B 11.5x 2.1x
Heron Therapeutics, Inc. /De/ HRTX ██% $226M x 15.8x
Hst Global, Inc. HSTC ██% $140M x 113.0x
Tuhura Biosciences, Inc./Nv HURA ██% $147M x 7.0x
Mindwalk Holdings Corp. HYFT ██% $56M x x
Hyperion Defi, Inc. HYPD ██% $46M x 1.1x
Ibio, Inc. IBIO ██% $57M x 1.0x
Impact Biomedical Inc. IBO ██% $71M x 5.6x
Ideaya Biosciences, Inc. IDYA ██% $2.55B x 2.5x
Inflarx N.V. IFRX ██% $150M x x
Igc Pharma, Inc. IGC ██% $31M x 4.2x
Immutep Ltd IMMP ██% $68M x x
Immix Biopharma, Inc. IMMX ██% $473M x 5.0x
Immunome Inc. IMNM ██% $2.60B x 4.1x
Imunon, Inc. IMNN ██% $11M x 1.6x
Immuron Ltd IMRN ██% $7M x x
Immuneering Corp IMRX ██% $339M x 1.6x
Eom Pharmaceutical Holdings, Inc. IMUC ██% $6M x 1.8x
Immunic, Inc. IMUX ██% $131M x x
Integrated Biopharma Inc INBP ██% $7M x 0.4x
Indaptus Therapeutics, Inc. INDP ██% $5M x 1.7x
Indivior Pharmaceuticals, Inc. INDV ██% $4.61B 18.3x x
Inmed Pharmaceuticals Inc. INM ██% $2M x 0.3x
Inovio Pharmaceuticals, Inc. INO ██% $91M x 3.8x
Insmed Inc INSM ██% $29.21B x 39.5x
Inhibitor Therapeutics, Inc. INTI ██% $16M x x
Innoviva, Inc. INVA ██% $1.70B 6.3x 1.5x
Io Biotech, Inc. IOBT ██% $540K x 0.6x
Io Biotech, Inc. IOBTQ ██% $350K x 0.4x
Ionis Pharmaceuticals Inc IONS ██% $12.40B x 25.2x
Opus Genetics, Inc. IRD ██% $359M x 23.4x
Disc Medicine, Inc. IRON ██% $2.50B x 3.4x
Ironwood Pharmaceuticals Inc IRWD ██% $673M 28.0x x
International Stem Cell Corp ISCO ██% $1M x x
Iterum Therapeutics Plc ITRM ██% $1M x x
Inventiva S.A. IVA ██% $1.07B x x
Incannex Healthcare Inc. IXHL ██% $61M x 0.8x
Jaguar Health, Inc. JAGX ██% $3M x 0.5x
Janux Therapeutics, Inc. JANX ██% $868M x 0.9x
Jazz Pharmaceuticals Plc JAZZ ██% $12.74B x 3.0x
Jade Biosciences, Inc. JBIO ██% $1.20B x 3.6x
Johnson & Johnson JNJ ██% $553.64B 26.3x 6.8x
Jupiter Neurosciences, Inc. JUNS ██% $14M x 246.4x
Kala Bio, Inc. KALA ██% $98M x x
Kalvista Pharmaceuticals, Inc. KALV ██% $1.37B x x
Kairos Pharma, Ltd. KAPA ██% $12M x 1.9x
Kaya Holdings, Inc. KAYS ██% $23M x x
Kamada Ltd KMDA ██% $470M x x
Kiniksa Pharmaceuticals International, Plc KNSA ██% $4.14B 56.7x 6.8x
Kiora Pharmaceuticals Inc KPRX ██% $7M -2.4x 0.3x
Karyopharm Therapeutics Inc. KPTI ██% $197M x x
Keros Therapeutics, Inc. KROS ██% $217M 2.5x 0.7x
Korro Bio, Inc. KRRO ██% $195M x 3.8x
Pasithea Therapeutics Corp. KTTA ██% $16M x 0.3x
Kura Oncology, Inc. KURA ██% $769M x 4.4x
Kyntra Bio, Inc. KYNB ██% $29M 0.2x x
Kezar Life Sciences, Inc. KZR ██% $54M x 0.8x
Lb Pharmaceuticals Inc LBRX ██% $898M x 3.0x
Legend Biotech Corp LEGN ██% $4.35B x x
Lexaria Bioscience Corp. LEXX ██% $16M x 2.5x
Lifecore Biomedical, Inc. \De\ LFCR ██% $190M x x
Lifevantage Corp LFVN ██% $67M 8.6x 2.0x
Ligand Pharmaceuticals Inc LGND ██% $2.78B 22.4x 2.7x
Longeveron Inc. LGVN ██% $25M x 4.4x
Lianbio LIANY ██% $13M x 0.1x
Lftd Partners Inc. LIFD ██% $3M 39.3x 0.1x
Lipella Pharmaceuticals Inc. LIPO ██% $230K x 0.2x
Lite Strategy, Inc. LITS ██% $43M x 0.5x
Lixte Biotechnology Holdings, Inc. LIXT ██% $40M x 4.1x
Lixte Biotechnology Holdings, Inc. LIXTW ██% $130K x 0.0x
Eli Lilly & Co LLY ██% $864.66B 34.2x 27.7x
Lunai Bioworks Inc. LNAI ██% $12M 7.3x x
Lipocine Inc. LPCN ██% $19M x 1.3x
Cypherpunk Technologies Inc. LPTX ██% $94M -1.1x 35.1x
Liquidia Corp LQDA ██% $3.42B x 76.4x
Larimar Therapeutics, Inc. LRMR ██% $422M x 5.4x
Lisata Therapeutics, Inc. LSTA ██% $28M x 1.9x
Lantern Pharma Inc. LTRN ██% $23M x 3.6x
Lava Therapeutics Nv LVTX ██% $46M x 3.6x
Lexicon Pharmaceuticals, Inc. LXRX ██% $682M x 6.3x
Lyell Immunopharma, Inc. LYEL ██% $441M x 1.8x
Maia Biotechnology, Inc. MAIA ██% $82M x 34.6x
Mustang Bio, Inc. MBIO ██% $6M x 0.6x
Moleculin Biotech, Inc. MBRX ██% $14M x 0.9x
Mbx Biosciences, Inc. MBX ██% $1.36B x 3.7x
Seres Therapeutics, Inc. MCRB ██% $70M 12.4x 1.6x
Medicus Pharma Ltd. MDCX ██% $11M x x
Medicus Pharma Ltd. MDCXW ██% $52M x x
Madrigal Pharmaceuticals, Inc. MDGL ██% $11.82B x 19.6x
Chrome Holding Co. MEHCQ ██% $96M x x
Macrogenics Inc MGNX ██% $196M x 3.5x
Mira Pharmaceuticals, Inc. MIRA ██% $44M x 4.2x
Mirum Pharmaceuticals, Inc. MIRM ██% $5.93B x 18.9x
Milestone Pharmaceuticals Inc. MIST ██% $191M x 4.6x
Moonlake Immunotherapeutics MLTX ██% $1.19B x 3.9x
Mineralys Therapeutics, Inc. MLYS ██% $2.17B x 3.4x
Mannkind Corp MNKD ██% $871M 148.6x x
Medicinova Inc MNOV ██% $68M x 1.7x
Monopar Therapeutics MNPR ██% $349M x 2.5x
Maplight Therapeutics, Inc. MPLT ██% $1.34B x 2.9x
Mereo Biopharma Group Plc MREO ██% $43M x 1.0x
Merck & Co., Inc. MRK ██% $281.35B 15.4x 5.4x
Marker Therapeutics, Inc. MRKR ██% $24M x 1.4x
Mersana Therapeutics, Inc. MRSN ██% $145M -3.4x -1.4x
Merus N.V. MRUS ██% $6.83B -13.5x 8.8x
Maravai Lifesciences Holdings, Inc. MRVI ██% $1.36B x 6.4x
Matinas Biopharma Holdings, Inc. MTNB ██% $4M x 0.9x
Metsera, Inc. MTSR ██% $7.41B x 22.0x
Metavia Inc. MTVA ██% $7M x 1.4x
Mural Oncology Plc MURA ██% $35M x 0.6x
Mainz Biomed N.V. MYNZ ██% $7M x x
Newamsterdam Pharma Co N.V. NAMS ██% $3.27B x 4.8x
Newamsterdam Pharma Co N.V. NAMSW ██% $2.59B x 3.6x
Natures Sunshine Products Inc NATR ██% $476M 24.4x 2.9x
Novabridge Biosciences NBP ██% $286M x 1.1x
Nanobiotix S.A. NBTX ██% $1.49B x x
Stablecoin Development Corp NBY ██% $37M x x
Newcelx Ltd. NCEL ██% $20M x 36.4x
Nucana Plc NCNA ██% $9M x x
Minerva Neurosciences, Inc. NERV ██% $284M x x
Neuphoria Therapeutics Inc. NEUP ██% $28M x 1.0x
Neurogene Inc. NGNE ██% $404M x 1.5x
Nika Pharmaceuticals, Inc NIKA ██% $421M x x
Nektar Therapeutics NKTR ██% $2.87B x 31.9x
Nkarta, Inc. NKTX ██% $201M x 0.6x
Newcelx Ltd. NLSP ██% $54M x 98.9x
Newcelx Ltd. NLSPW ██% $120K x 0.2x
Nanoviricides, Inc. NNVC ██% $27M x 2.4x
Nurix Therapeutics, Inc. NRIX ██% $1.73B x 3.6x
Neurosense Therapeutics Ltd. NRSN ██% $29M x x
Nrx Pharmaceuticals, Inc. NRXP ██% $95M x x
Neonc Technologies Holdings, Inc. NTHI ██% $111M x x
Nuvation Bio Inc. NUVB ██% $1.52B x 5.0x
Nuvalent, Inc. NUVL ██% $7.29B x 5.8x
Nuvectis Pharma, Inc. NVCT ██% $220M x 11.9x
Novartis Ag NVS ██% $282.12B x x
Northwest Biotherapeutics Inc NWBO ██% $321M x x
Nexien Biopharma, Inc. NXEN ██% $10K x x
Nextcure, Inc. NXTC ██% $32M x 0.9x
Nexentis Technologies Inc. NXTS ██% $3M x 0.2x
Ocean Biomedical, Inc. OCEA ██% $190K -0.3x 0.1x
Ocular Therapeutix, Inc OCUL ██% $2.02B x 3.1x
Oragenics Inc OGEN ██% $3M x 0.3x
Organigram Global Inc. OGI ██% $198M x x
Organon & Co. OGN ██% $3.45B 18.5x 4.6x
Onkure Therapeutics, Inc. OKUR ██% $216M x 3.9x
Olema Pharmaceuticals, Inc. OLMA ██% $1.17B x 2.5x
Omeros Corp OMER ██% $1.05B x x
Beone Medicines Ltd. ONC ██% $32.81B 114.4x 7.5x
Onconetix, Inc. ONCO ██% $7M x 0.5x
Oncolytics Biotech Inc ONCY ██% $102M x x
Opko Health, Inc. OPK ██% $858M x 0.7x
Organogenesis Holdings Inc. ORGO ██% $298M 8.1x 1.0x
Orgenesis Inc. ORGS ██% $3M x x
Oric Pharmaceuticals, Inc. ORIC ██% $973M x 2.5x
Oruka Therapeutics, Inc. ORKA ██% $4.09B x 8.7x
Oramed Pharmaceuticals Inc. ORMP ██% $152M 2.4x 0.8x
Os Therapies Inc OSTX ██% $74M x x
Oncotelic Therapeutics, Inc. OTLC ██% $18M x 2.0x
Ovid Therapeutics Inc. OVID ██% $484M x 3.7x
One World Products, Inc. OWPC ██% $620K x x
Phibro Animal Health Corp PAHC ██% $2.16B 25.3x 6.5x
Prestige Consumer Healthcare Inc. PBH ██% $2.65B 14.2x 1.5x
Psyence Biomedical Ltd. PBM ██% $15M x x
Puma Biotechnology, Inc. PBYI ██% $379M 12.2x 2.9x
Pacira Biosciences, Inc. PCRX ██% $1.00B 195.0x 1.5x
Processa Pharmaceuticals, Inc. PCSA ██% $7M x 1.2x
Procyon Corp PCYN ██% $2M x 0.7x
Pds Biotechnology Corp PDSB ██% $54M x 5.9x
Pepgen Inc. PEPG ██% $113M x 0.8x
Pfizer Inc PFE ██% $151.74B 19.5x 1.8x
Precigen, Inc. PGEN ██% $1.47B x 70.4x
Phathom Pharmaceuticals, Inc. PHAT ██% $890M x x
Phio Pharmaceuticals Corp. PHIO ██% $14M x 0.7x
Pharvaris N.V. PHVS ██% $2.03B x x
Protokinetix, Inc. PKTX ██% $2M x 8.4x
Plandai Biotechnology, Inc. PLPL ██% $4M x 14.6x
Pliant Therapeutics, Inc. PLRX ██% $75M x 0.4x
Polomar Health Services, Inc. PMHS ██% $3M x 0.4x
Promis Neurosciences Inc. PMN ██% $99M x x
Pmv Pharmaceuticals, Inc. PMVP ██% $74M x 0.7x
Purple Biotech Ltd. PPBT ██% $6M x x
Propanc Biopharma, Inc. PPCB ██% $2M x 0.2x
Praxis Precision Medicines, Inc. PRAX ██% $8.03B x 9.2x
Prf Technologies Ltd. PRFX ██% $2M x 0.2x
Perrigo Co Plc PRGO ██% $1.63B x 0.6x
Prelude Therapeutics Inc PRLD ██% $402M x 5.9x
Prophase Labs, Inc. PRPH ██% $620K x 0.1x
Proqr Therapeutics N.V. PRQR ██% $165M x x
Prothena Corp Public Ltd Co PRTA ██% $595M x 2.1x
Ptc Therapeutics, Inc. PTCT ██% $5.30B 7.8x x
Protagonist Therapeutics, Inc PTGX ██% $6.16B x 10.0x
Protagenic Therapeutics, Inc.\New PTIX ██% $2M x x
Palatin Technologies Inc PTN ██% $37M x 3.3x
Palatin Technologies Inc PTNT ██% $17M x 43.1x
Petros Pharmaceuticals, Inc. PTPI ██% $300K 0.1x 0.1x
Pulmatrix, Inc. PULM ██% $5M x 1.2x
Provectus Biopharmaceuticals, Inc. PVCT ██% $24M x x
Palvella Therapeutics, Inc. PVLA ██% $1.84B x 65.6x
Pyxis Oncology, Inc. PYXS ██% $107M x 2.0x
Aixcrypto Holdings, Inc. QLGN ██% $8M -1.3x 0.2x
Quoin Pharmaceuticals, Ltd. QNRX ██% $12M x 0.9x
Quantum Biopharma Ltd. QNTM ██% $33M x x
Q32 Bio Inc. QTTB ██% $95M 3.2x 2.3x
Quantum Cyber N.V. QUCY ██% $5M x 8.3x
Uniqure N.V. QURE ██% $1.24B x 6.3x
Radiopharm Theranostics Ltd RADX ██% $34M x x
Rani Therapeutics Holdings, Inc. RANI ██% $111M x 3.4x
Rapport Therapeutics, Inc. RAPP ██% $1.58B x 3.3x
Rapt Therapeutics, Inc. RAPT ██% $1.56B -0.4x 10.3x
Ultragenyx Pharmaceutical Inc. RARE ██% $2.39B x x
Rocket Pharmaceuticals, Inc. RCKT ██% $377M x 1.4x
Arcus Biosciences, Inc. RCUS ██% $3.20B x 5.1x
Dr Reddys Laboratories Ltd RDY ██% $11.39B x x
Regeneron Pharmaceuticals, Inc. REGN ██% $73.25B 16.6x 2.3x
Revelation Biosciences, Inc. REVB ██% $4M x 0.5x
Rafael Holdings, Inc. RFL ██% $65M x 0.8x
Regen Biopharma Inc RGBP ██% $60K x x
Regen Biopharma Inc RGBPP ██% $470K x x
Rigel Pharmaceuticals Inc RIGL ██% $529M 1.4x 1.4x
Relmada Therapeutics, Inc. RLMD ██% $801M x 9.3x
Rallybio Corp RLYB ██% $48M x 0.8x
Retrieve Medical Holdings, Inc. RMHI ██% $27M x x
Rockwell Medical, Inc. RMTI ██% $35M x 0.9x
Avidity Biosciences, Inc. RNA ██% $206M -12.2x 0.1x
Cartesian Therapeutics, Inc. RNAC ██% $178M x x
Transcode Therapeutics, Inc. RNAZ ██% $7M x 5.2x
Rein Therapeutics, Inc. RNTX ██% $37M x 2.2x
Renovorx, Inc. RNXT ██% $38M x 7.1x
Roivant Sciences Ltd. ROIV ██% $20.25B x 4.7x
Royalty Pharma Plc RPRX ██% $29.69B 38.5x 4.6x
Repare Therapeutics Inc. RPTX ██% $114M -2.1x 1.0x
Rest Ez Inc. RTEZ ██% $1.93B x x
Rapid Therapeutic Science Laboratories, Inc. RTSL ██% $110K 1.9x 0.3x
Reviva Pharmaceuticals Holdings, Inc. RVPH ██% $11M x 1.3x
Rhythm Pharmaceuticals, Inc. RYTM ██% $5.47B x 39.3x
Rezolute, Inc. RZLT ██% $318M x 2.5x
Filana Therapeutics, Inc. SAVA ██% $101M -1.9x 1.2x
Sunshine Biopharma Inc. SBFM ██% $5M x 0.2x
Scienture Holdings, Inc. SCNX ██% $16M x 0.2x
Scpharmaceuticals Inc. SCPH ██% $302M -2.0x -50.9x
Scorpius Holdings, Inc. SCPX ██% $610K x x
Scynexis Inc SCYX ██% $74M x 1.5x
Stablecoin Development Corp SDEV ██% $33M x x
Schrodinger, Inc. SDGR ██% $878M x 2.4x
Septerna, Inc. SEPN ██% $1.06B x 2.8x
Serina Therapeutics, Inc. SER ██% $27M x x
Sagimet Biosciences Inc. SGMT ██% $496M x 4.5x
Shuttle Pharmaceuticals Holdings, Inc. SHPH ██% $6M x 2.6x
Siga Technologies Inc SIGA ██% $329M 14.2x 1.7x
Silo Pharma, Inc. SILO ██% $7M x 1.1x
Sionna Therapeutics, Inc. SION ██% $1.73B x 5.6x
Skinvisible, Inc. SKVI ██% $1M x x
Skye Bioscience, Inc. SKYE ██% $29M x 1.5x
Sol-Gel Technologies Ltd. SLGL ██% $240M x 10.5x
Silence Therapeutics Plc SLN ██% $345M x 5.5x
Silence Therapeutics Plc SLNCF ██% $213M x 2.9x
Soleno Therapeutics Inc SLNO ██% $2.75B 131.8x 6.1x
Salarius Pharmaceuticals, Inc. SLRX ██% $2M -0.5x 0.4x
Sellas Life Sciences Group, Inc. SLS ██% $913M x 12.9x
Summit Therapeutics Inc. SMMT ██% $16.65B x 30.5x
Semnur Pharmaceuticals, Inc. SMNR ██% $1.84B x x
Syndax Pharmaceuticals Inc SNDX ██% $1.90B x 45.6x
Soligenix, Inc. SNGX ██% $4M x 0.7x
Sibannac, Inc. SNNC ██% $2M x x
Sensei Biotherapeutics, Inc. SNSE ██% $34M x 1.8x
Sanofi SNY ██% $111.60B x x
Sonnet Biotherapeutics Holdings, Inc. SONN ██% $4M -1.6x 29.5x
Spruce Biosciences, Inc. SPRB ██% $155M x 3.6x
Scisparc Ltd. SPRC ██% $5M x x
Spero Therapeutics, Inc. SPRO ██% $142M 16.5x 2.4x
Ars Pharmaceuticals, Inc. SPRY ██% $820M x 7.2x
Sarepta Therapeutics, Inc. SRPT ██% $2.19B x 1.9x
Stoke Therapeutics, Inc. STOK ██% $1.93B x 5.5x
Shattuck Labs, Inc. STTK ██% $540M x 6.6x
Supernus Pharmaceuticals, Inc. SUPN ██% $2.76B x 2.6x
Savara Inc SVRA ██% $1.07B x 5.3x
60 Degrees Pharmaceuticals, Inc. SXTP ██% $4M x 1.2x
Synlogic, Inc. SYBX ██% $7M x 0.6x
Spyre Therapeutics, Inc. SYRE ██% $5.82B x 8.1x
Syros Pharmaceuticals, Inc. SYRS ██% $20K -0.1x -0.4x
Takeda Pharmaceutical Co Ltd TAK ██% $52.70B x x
Theravance Biopharma, Inc. TBPH ██% $852M 8.1x 2.9x
Alaunos Therapeutics, Inc. TCRT ██% $6M x 2.9x
Telomir Pharmaceuticals, Inc. TELO ██% $96M x 16.3x
Tenax Therapeutics, Inc. TENX ██% $338M x 3.5x
Terns Pharmaceuticals, Inc. TERN ██% $6.11B x 6.1x
Teva Pharmaceutical Industries Ltd TEVA ██% $40.84B 26.1x 5.0x
Teva Pharmaceutical Industries Ltd TEVJF ██% $38.09B 53.4x 5.3x
Tg Therapeutics, Inc. TGTX ██% $5.25B 11.7x 8.1x
Canton Strategic Holdings, Inc. THAR ██% $186M x 30.2x
Talphera, Inc. TLPH ██% $45M x 2.6x
Telix Pharmaceuticals Ltd TLX ██% $3.73B x x
Tango Therapeutics, Inc. TNGX ██% $2.98B x 8.6x
Tonix Pharmaceuticals Holding Corp. TNXP ██% $166M x 0.7x
Theriva Biologics, Inc. TOVX ██% $17M x 1.1x
Tempest Therapeutics, Inc. TPST ██% $29M x 4.4x
Traws Pharma, Inc. TRAW ██% $17M -0.6x 1.5x
Entrada Therapeutics, Inc. TRDA ██% $513M x 1.7x
Trevi Therapeutics, Inc. TRVI ██% $1.77B x 9.7x
Trevena Inc TRVN ██% $260K -1.3x 1.5x
Turn Therapeutics Inc. TTRX ██% $111M x 23.7x
Tvardi Therapeutics, Inc. TVRD ██% $29M x 1.4x
Travere Therapeutics, Inc. TVTX ██% $3.94B x 34.3x
Therapeuticsmd, Inc. TXMD ██% $24M x 0.9x
Tyra Biosciences, Inc. TYRA ██% $1.84B x 7.1x
Unicycive Therapeutics, Inc. UNCY ██% $192M x 6.4x
Upstream Bio, Inc. UPB ██% $501M x 1.5x
Urogen Pharma Ltd. URGN ██% $1.17B x x
United Therapeutics Corp UTHR ██% $24.92B 18.7x 3.5x
Vaccinex, Inc. VCNX ██% $2M x x
Vera Therapeutics, Inc. VERA ██% $2.54B x 4.2x
Veru Inc. VERU ██% $39M -0.8x 2.1x
Vg Life Sciences Inc. VGLS ██% $660K x x
Vicapsys Life Sciences, Inc. VICP ██% $47M x x
Vincerx Pharma, Inc. VINC ██% $70K -0.2x 0.0x
Viracta Therapeutics, Inc. VIRX ██% $390K -0.2x 0.2x
Viking Therapeutics, Inc. VKTX ██% $3.54B x 7.1x
Vanda Pharmaceuticals Inc. VNDA ██% $423M x 1.3x
Verrica Pharmaceuticals Inc. VRCA ██% $111M x 4.5x
Viridian Therapeutics, Inc.\De VRDN ██% $1.35B x 1.9x
Vireo Growth Inc. VREOF ██% $348M x 1.4x
Verona Pharma Plc VRNA ██% $73.55B -185.1x 264.3x
Virpax Pharmaceuticals, Inc. VRPX ██% $160K 0.0x -19.5x
Vertex Pharmaceuticals Inc / Ma VRTX ██% $108.15B 27.4x 5.8x
Verastem, Inc. VSTM ██% $488M x 8.5x
Vistagen Therapeutics, Inc. VTGN ██% $26M x 0.5x
Viatris Inc VTRS ██% $17.40B x 1.1x
Vtv Therapeutics Inc. VTVT ██% $0.00M -3.3x -7.5x
Ventyx Biosciences, Inc. VTYX ██% $999M -1.0x 5.2x
Vyne Therapeutics Inc. VYNE ██% $21M x 0.8x
Whitehawk Therapeutics, Inc. WHWK ██% $182M x 1.3x
Wave Life Sciences Ltd. WVE ██% $1.36B x 2.7x
Xenetic Biosciences, Inc. XBIO ██% $7M x 0.9x
Xbiotech Inc. XBIT ██% $78M x 0.6x
Exicure, Inc. XCUR ██% $20M x 5.2x
Xenon Pharmaceuticals Inc. XENE ██% $5.52B x 9.5x
Xeris Biopharma Holdings, Inc. XERS ██% $1.05B 1887.0x 76.4x
Xilio Therapeutics, Inc. XLO ██% $50M x 1.4x
Xencor Inc XNCR ██% $898M x 1.4x
Xoma Royalty Corp XOMA ██% $485M 15.3x 5.8x
Xoma Royalty Corp XOMAO ██% $312M 14.4x 3.6x
Xoma Royalty Corp XOMAP ██% $326M 15.1x 3.7x
Xtl Biopharmaceuticals Ltd XTLB ██% $9M x x
Zenas Biopharma, Inc. ZBIO ██% $1.20B x 5.0x
Zai Lab Ltd ZLAB ██% $2.42B x 3.4x
Zentalis Pharmaceuticals, Inc. ZNTL ██% $280M x 1.3x
Zomedica Corp. ZOMDF ██% $132M x 1.1x
Zoetis Inc. ZTS ██% $48.76B 18.2x 14.6x
Zevra Therapeutics, Inc. ZVRA ██% $575M 6.9x 3.7x
Zyversa Therapeutics, Inc. ZVSA ██% $2M x x
Zymeworks Inc. ZYME ██% $1.75B -8.3x 6.5x
Reveal all forecasts See exact % predictions for all competitors
Sign up free

Frequently Asked Questions - Merus N.V. Stock Forecast

How accurate are Merus N.V. stock predictions?

Our AI model shows a -15% Spearman correlation coefficient for MRUS predictions, based on advanced machine learning algorithms trained on over 10 years of market data. This measures the strength of the monotonic relationship between predicted and actual price movements.

What factors influence Merus N.V. stock price forecasts?

Our analysis considers Merus N.V.'s financial metrics, Life Sciences sector trends, market sentiment, technical indicators, earnings data, and macroeconomic factors affecting stock performance.

Is Merus N.V. a good investment in 2025?

Based on our AI analysis, Merus N.V. shows potential for various market scenarios. Consider your risk tolerance, investment timeline, and portfolio diversification before making investment decisions.

How often are Merus N.V. forecasts updated?

Merus N.V. stock forecasts are updated daily using real-time market data, ensuring you receive the most current AI-powered predictions and investment insights.

Want a simpler view of Merus N.V.?

View simplified analysis on AI Stock Finder →

My Portfolio

Investment Dashboard

Loading your portfolio...